MRSN Mersana Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRSN

Price (delayed)

$3.36

Market cap

$407.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.48

Enterprise value

$266.65M

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives ...

Highlights
Mersana Therapeutics's EPS has increased by 32% YoY and by 16% from the previous quarter
Mersana Therapeutics's net income has increased by 16% YoY and by 13% QoQ
Mersana Therapeutics's revenue has increased by 39% YoY but it has decreased by 10% from the previous quarter
The gross profit has grown by 39% YoY but it has contracted by 10% from the previous quarter
The equity has plunged by 60% YoY and by 29% from the previous quarter
MRSN's quick ratio is down by 7% since the previous quarter and by 2.9% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.mersana.com
Peers: OMER OMGA

Key stats

What are the main financial stats of MRSN
Market
Shares outstanding
121.3M
Market cap
$407.58M
Enterprise value
$266.65M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.98
Price to sales (P/S)
10.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.24
Earnings
Revenue
$36.86M
EBIT
-$167.6M
EBITDA
-$163.3M
Free cash flow
-$171.05M
Per share
EPS
-$1.48
Free cash flow per share
-$1.47
Book value per share
$0.31
Revenue per share
$0.32
TBVPS
$1.95
Balance sheet
Total assets
$226.06M
Total liabilities
$189.16M
Debt
$33.63M
Equity
$36.9M
Working capital
$150.42M
Liquidity
Debt to equity
0.91
Current ratio
3.36
Quick ratio
3.29
Net debt/EBITDA
0.86
Margins
EBITDA margin
-443.1%
Gross margin
100%
Net margin
-465.8%
Operating margin
-487.5%
Efficiency
Return on assets
-62.6%
Return on equity
-282.4%
Return on invested capital
-201.6%
Return on capital employed
-103.2%
Return on sales
-454.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRSN stock price

How has the Mersana Therapeutics stock price performed over time
Intraday
-0.3%
1 week
17.89%
1 month
-20.38%
1 year
-23.29%
YTD
44.83%
QTD
-25%

Financial performance

How have Mersana Therapeutics's revenue and profit performed over time
Revenue
$36.86M
Gross profit
$36.86M
Operating income
-$179.67M
Net income
-$171.67M
Gross margin
100%
Net margin
-465.8%
Mersana Therapeutics's revenue has increased by 39% YoY but it has decreased by 10% from the previous quarter
The net margin has grown by 39% YoY and by 3.5% from the previous quarter
The gross profit has grown by 39% YoY but it has contracted by 10% from the previous quarter
The operating margin rose by 36% year-on-year and by 2.4% since the previous quarter

Growth

What is Mersana Therapeutics's growth rate over time

Valuation

What is Mersana Therapeutics stock price valuation
P/E
N/A
P/B
10.98
P/S
10.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.24
Mersana Therapeutics's EPS has increased by 32% YoY and by 16% from the previous quarter
The stock's P/B is 139% more than its 5-year quarterly average of 4.6 and 103% more than its last 4 quarters average of 5.4
The equity has plunged by 60% YoY and by 29% from the previous quarter
The stock's P/S is 100% below its 5-year quarterly average of 2806.2 but 23% above its last 4 quarters average of 8.6
Mersana Therapeutics's revenue has increased by 39% YoY but it has decreased by 10% from the previous quarter

Efficiency

How efficient is Mersana Therapeutics business performance
MRSN's return on equity has dropped by 58% year-on-year and by 7% since the previous quarter
Mersana Therapeutics's ROS has increased by 40% YoY and by 3.8% from the previous quarter
The ROIC has contracted by 20% from the previous quarter but it has grown by 19% YoY
The ROA is up by 11% year-on-year and by 4.3% since the previous quarter

Dividends

What is MRSN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRSN.

Financial health

How did Mersana Therapeutics financials performed over time
The company's total assets is 20% higher than its total liabilities
The company's total assets fell by 32% YoY and by 14% QoQ
The total liabilities has declined by 22% year-on-year and by 10% since the previous quarter
The debt is 9% less than the equity
The company's debt to equity has surged by 133% YoY and by 38% QoQ
The equity has plunged by 60% YoY and by 29% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.